trustmebro.to/r/…
✓ checked
trust me, bro:
here is the receipt.
the claim

The US FDA approved lenacapavir (Yeztugo), a twice-yearly injection, for HIV pre-exposure prophylaxis in June 2025.

the verdict
SUPPORTED
the evidence backs this
Recorded sources
8 sources for · 0 against

Counts group repeated records of the same source within each side. They do not measure evidence strength or source independence.

Is it true that the US FDA approved lenacapavir (Yeztugo), a twice-yearly injection, for HIV pre-exposure prophylaxis in June 2025?

Yes. Multiple peer-reviewed sources state that the FDA approved lenacapavir (Yeztugo) on 18 June 2025 for HIV pre-exposure prophylaxis, given as a twice-yearly subcutaneous injection. A Wikipedia article and a drug review confirm the US June approval and twice-yearly PrEP indication without naming the year.

Verdict: SUPPORTED · 8 sources for, 0 against · Last checked

The private library was unavailable for some searches in this check. Missing library results are not evidence against the claim.

Evidence for · 8
Pre-exposure prophylaxis for HIV prevention
Get citation
Pre-exposure prophylaxis for HIV prevention. (n.d.). en.wikipedia.org. https://en.wikipedia.org/wiki/Pre-exposure_prophylaxis_for_HIV_prevention

See more details
More for · 7
Lenacapavir (Yeztugo) for HIV Pre-Exposure Prophylaxis
2025
Get citation
Lenacapavir (Yeztugo) for HIV Pre-Exposure Prophylaxis. (2025). doi.org. https://doi.org/10.58347/tml.2025.1735c

Lenacapavir: A Review in HIV Pre-Exposure Prophylaxis.
2026
Get citation
HA, B. (2026). Lenacapavir: A Review in HIV Pre-Exposure Prophylaxis.. doi.org. https://doi.org/10.1007/s40265-026-02368-0

Twice-Yearly Injectable Pre-Exposure Prophylaxis With Lenacapavir: Redefining Adherence and Access in the Global Fight Against HIV
2025
Get citation
Sah, S., Iqbal, U., Mishra, T., Ullah, N., & Yadav, T. (2025). Twice-Yearly Injectable Pre-Exposure Prophylaxis With Lenacapavir: Redefining Adherence and Access in the Global Fight Against HIV. doi.org. https://doi.org/10.1177/23259582251390622

Clinical Recommendation for the Use of Injectable Lenacapavir as HIV Preexposure Prophylaxis — United States, 2025 | MMWRMinusSASstats
Get citation
Clinical Recommendation for the Use of Injectable Lenacapavir as HIV Preexposure Prophylaxis — United States, 2025 | MMWRMinusSASstats. (n.d.). cdc.gov. https://www.cdc.gov/mmwr/volumes/74/wr/mm7435a1.htm

Breaking barriers in HIV management: the rise of long-acting lenacapavir
2025
Get citation
Breaking barriers in HIV management: the rise of long-acting lenacapavir. (2025). doi.org. https://doi.org/10.1097/ms9.0000000000003775

FDAs new approval: yeztugo (lenacapavir): a longer lasting avenue against HIV
2026
Get citation
FDAs new approval: yeztugo (lenacapavir): a longer lasting avenue against HIV. (2026). doi.org. https://doi.org/10.47391/jpma.33073

LENACAPAVIR: A NOVEL CAPSID INHIBITOR TRANSFORMING HIV MANAGEMENT
2025
Get citation
LENACAPAVIR: A NOVEL CAPSID INHIBITOR TRANSFORMING HIV MANAGEMENT. (2025). doi.org. https://doi.org/10.5281/zenodo.17766928

Receipt History
Anyone with this link can read the claim and its public receipt, including any personal information in that text. Open permanent receipt.
Check your own claim
Challenge the receipt
Requests are recorded for review. This does not start an automatic check or guarantee a response time.

Citation formatting by citeproc-js (Frank Bennett) and the Citation Style Language project. Source and licenses.

This receipt is an automated verdict against our published method · not an opinion about any author or publication.
Terms · Privacy · How verdicts work